2010 | 2009 | 2008                                                      DSPA 2009 Press Releases

Date	Title
12/03/08	Results of Studies of Eslicarbazepine Acetate for the Treatment of Epilepsy to Be Presented at American Epilepsy Society Annual Meeting
11/10/08	Results of Studies of ALVESCO® for the Treatment of Asthma and OMNARIS™ in an HFA Nasal Aerosol Presented at American College of Allergy, Asthma & Immunology Annual Meeting
10/28/08	Sepracor Inc. Reports 9.6% Increase in Revenue for Third Quarter and Tightens Range for Full-Year 2008 Financial Guidance
10/24/08	European Medicines Agency (EMEA) Issues Positive Opinion For LUNIVIA® (Eszopiclone) Marketing Authorization Application (MAA) In Europe
10/21/08	Sepracor Inc. Sets Conference Call and Webcast for Third Quarter Operating Results
09/24/08	New Data Show Efficacy and Safety of Eslicarbazepine Acetate in the Treatment of Epilepsy
09/08/08	ALVESCO® (Ciclesonide) Inhalation Aerosol Now Available in U.S. for Treatment of Asthma
09/03/08	LUNESTA® Next-Day Function and Discontinuation Data from a Long-Term 12-Week Study in Elderly Patients Presented at ECNP
08/19/08	Sepracor Announces Senior Management Appointments
07/29/08	Sepracor Inc. Reports Second Quarter 2008 Results
07/25/08	Sepracor Inc. Sets Conference Call and Webcast for Second Quarter Operating Results
07/14/08	Sepracor Announces Full Support of PhRMA's Revised Code on Interactions with Healthcare Professionals
06/27/08	Sepracor Inc. Presented Leadership Award for Contributions to Growth of Community
06/19/08	Sepracor Announces Phase III Data for Eslicarbazepine Acetate Presented at Ninth Eilat Conference on New Anti-Epileptic Drugs
06/03/08	Sepracor Completes Acquisition of Oryx Pharmaceuticals and Expands Operations in Canada
05/15/08	Sepracor Names Robert F. Scumaci as Chief Financial Officer
05/15/08	David P. Southwell to Resign as Chief Financial Officer of Sepracor
05/12/08	LUNESTA® Study of Patients with Insomnia and Co-Morbid Generalized Anxiety Disorder (GAD) Published in Archives of General Psychiatry
05/01/08	Sepracor Inc. Reports First Quarter 2008 Results, Certain Strategic Initiatives and Settlement of XOPENEX® Patent Litigation with Breath Limited
05/01/08	Sepracor to Acquire Oryx Pharmaceuticals Inc. and Expand Commercial Operations into Canada
05/01/08	Sepracor and Arrow Sign Global License and Development Agreement Covering Technology to Enhance Ciclesonide and BROVANA® Franchises
05/01/08	Sepracor Announces Final Settlement of XOPENEX(R) Inhalation Solution Patent Infringement Litigation with Breath Limited
05/01/08	Sepracor and Arrow Sign Global License and Development Agreement for XOPENEX®/Ipratropium Inhalation Solution Combination
04/28/08	Sepracor Inc. Sets Conference Call and Webcast for First Quarter Operating Results
04/22/08	Sepracor Launches "My Allergies in America" Web Site, a New Online Resource for Physicians and Nasal Allergy Sufferers
04/17/08	OMNARIS™ Nasal Spray Now Available by Prescription for Patients with Seasonal and Perennial Allergies
03/17/08	Sepracor Presents OMNARIS™ HFA Nasal Aerosol Large-Scale Phase II Study Data at American Academy of Allergy Asthma and Immunology (AAAAI)
03/17/08	Sepracor Presents Safety Data on OMNARIS™ AQ and OMNARIS™ HFA Nasal Sprays at American Academy of Allergy Asthma and Immunology (AAAAI)
03/14/08	Sepracor Announces Passing of Board Member James G. Andress
02/29/08	Sepracor Inc. Reports 2007 Fourth Quarter and Full-Year Results, Forecasts Stronger Revenue Growth for 2008
02/26/08	Sepracor Inc. Sets Conference Call and Webcast for Fourth Quarter and Full-Year 2007 Operating Results
01/28/08	Sepracor Announces Internal Review of Government Price Reporting Matters
01/28/08	Sepracor Acquires Exclusive U.S. Rights to Nycomed's ALVESCO® HFA and OMNARIS™ AQ Products as Well as Ciclesonide Pipeline
01/03/08	Timothy J. Barberich to Resign as Executive Chairman of Sepracor and Will Continue to Serve as Chairman of the Board
01/02/08	Sepracor Inc. and Bial Announce Exclusive Licensing Agreement for Development and Commercialization of Anti-Epileptic Compound in United States and Canada